Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.

@article{Dinarello1991BlockingII,
  title={Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.},
  author={Charles A Dinarello and Robert A. Thompson},
  journal={Immunology today},
  year={1991},
  volume={12 11},
  pages={404-10}
}
Clinical and experimental evidence suggests that shock, arthritis, osteoporosis, colitis, leukemia, diabetes, wasting and atherosclerosis are mediated, in part, by interleukin 1 (IL-1). Inhibition of this cytokine has been a strategy for studying disease and for new drug development. A naturally-occurring IL-1 inhibitor (IL-1 receptor antagonist, IL-1ra) that blocks binding of IL-1 to its receptors has been cloned and produced in recombinant organisms. IL-1ra reduces the severity of sepsis… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 153 extracted citations

Sepsis and cytokines: current status.

British journal of anaesthesia • 1996
View 8 Excerpts
Highly Influenced

Platelet-activated serum might have a therapeutic effect on damaged articular cartilage.

Journal of tissue engineering and regenerative medicine • 2017
View 1 Excerpt
Highly Influenced

Similar Papers

Loading similar papers…